Ruthigen, Oxford Immunotech plan IPOs; Isis earns $10M payment from Biogen Idec for muscular dystropy drug work;

@FierceBiotech: ICYMI yesterday: The top Phase III R&D setbacks of 2013. Feature | Follow @FierceBiotech

@JohnCFierce: Third Rock startup banks $20M to fuel next leg of CNS drug development journey. News | Follow @JohnCFierce

@DamianFierce: St. Jude boosts profits as job cuts, M&A pay off. Article | Follow @DamianFierce

@EmilyMFierce: Georgetown University Medical Center researchers find a vegetable-based compound that protects against side effects of radiation therapy. Article from FierceBiotech Research | Follow @EmilyMFierce

> Santa Barbara, CA-based Ruthigen plans to raise $20 million by offering 1.5 million shares at a price range of $12 to $14. Item

> Isis Pharmaceuticals ($ISIS), of Carlsbad, CA, has earned a $10 million milestone payment from Biogen Idec ($BIIB) for the advancement of its drug candidate ISIS-DMPK(Rx) to treat myotonic dystrophy type I. Release

> Tuberculosis diagnostics maker Oxford Immunotec Global is planning an initial public offering that could raise more than $86 million. Story

> Louisville, KY-based GlobeImmune has received an undisclosed amount of money in a milestone payment from Gilead Sciences ($GILD) under a 2011 deal with the company to develop and commercialize Tarmogen products. More

Medical Device News

@FierceMedDev: ICYMI yesterday: FierceMedicalDevices' 2013 Fierce 15. Feature | Follow @FierceMedDev

> TB Dx maker Oxford Immunotec to pursue IPO path. Report

> Myriad vs. Quest over BRCA testing: It's getting serious. More

> Abbott posts med tech growth thanks to diagnostics, dealmaking. Story

Pharma News

@FiercePharma: Top news online yesterday: J&J hikes earnings forecast on pharma's superhero sales flight. Story | Follow @FiercePharma

@EricPFierce: MHRA says it also took action against Wockhardt contractor Nestor in U.K. as part of recent action. Article from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: Look out, Vivus--Eisai to double Belviq sales force by December 2013. Release | Follow @CarlyHFierce

> Sanofi invests in Fabrazyme production as sales soar. Report

> Teva halts Israeli layoff plans amid pressure from labor, government. Article

> Telegraph: GlaxoSmithKline's ex-China chief barred from leaving country. Story

Biomarkers News

> Biomarker differentiates ADHD subtypes, offers clues for treatment. Article

> Amgen taps KineMed for Alzheimer's biomarkers. Report

> Skin may conceal a viable Parkinson's biomarker. Story

Drug Delivery News

@MichaelGFierce: AstraZeneca teams with Taris to research bladder cancer delivery device. Story | Follow @MichaelGFierce

> Mini-pancreas grown from stem cells has implications for future insulin delivery. More

> Cell membrane models 'written' on graphene provide drug-delivery model. Item

> Study: Synthetic RNA conjugates target, silence bacteria's genetic material. Article

> Nanoparticle hydrogel heats up to release drugs in active cartilage. Story

Diagnostics News

@MarkHFierce: Smith & Nephew will handle U.S. distribution of a women's care diagnostic device developed by Femasys. Story | Follow @MarkHFierce

> Applied Proteomics to develop pancreatic and colon cancer Dx with German research institute. More

> Quest preemptively sues Myriad to ensure new BRCA test avoids patent violation. Report

> CardioDx's proposed $86.2M IPO will aid marketing and insurance coverage efforts. Story

> New blood test screens for irritable bowel syndrome. Article

> Mount Sinai's Icahn School of Medicine jumps into Dx, drug development. Item

Suggested Articles

When thinking about clinical research patient recruitment, a crucial step is building effective patient recruitment advertising campaigns.

Novavax delayed the start of a large phase 3 trial for its COVID-19 vaccine in the U.S. and Mexico, thanks to delays in scaling up manufacturing.

The decision to dump IL33r antagonist GSK3772847 follows lackluster clinical data on rival candidates against the same target.